Netakimab in the treatment of psoriatic erythroderma

Psoriasis is considered as system immunoassociated disease of the multifactorial nature with dominating value in development of genetic factors. Suffer псориазом from 2 to 7% of inhabitants of a planet. Psoriasis it is started, when environment factors activate plasmocytoid dentrid cages that leads to development numerous proinflammatory citokines, including the factor некроза to a tumour FNO-α, interferon (IFN) γ, interleukin (IL) 17, IL-22, IL-23 and IL-1β. Many of these citokines stimulate hyperproliferation keratinocyes which supports a chronic inflammation. The heaviest form psoriasis – psoriatic erythroderma, results adverse экзогенных from the factors, irritating treatment. Develops erythroderma at 1.5–3% of patients псориазом which amazes all surface of an integument. All skin cover gets brightly red colour, with a brown shade, is strained. Taking into account recent achievements in understanding of the inflammatory nature psoriatic research efforts have been concentrated to finding-out of a role specific proinflammatory cytokines which participate in pathogenesis diseases, for the purpose of working out of new purposeful methods of treatment. For treatment psoriatic erythroderma in medicine there is a wide spectrum of external and system means. Undoubtedly, psoriatic erythroderma has all indications to appointment of biological therapy, especially when does not give in traditional methods. Authors of article have presented a therapy material psoriatic erythroderma, a domestic preparation of genno-engineering biological therapy of (netakimab). The good clinical effect that opens prospect of application of this preparation is gained. The concrete clinical example of successful treatment is resulted.